These results suggested that although pembrolizumab was not superior to paclitaxel as a 2nd-line therapy in the overall patients, it exhibited better survival in patients with higher tumor PD-L1 expression (CPS ≥ 10%) compared with paclitaxel [19]. This evidence concerns the gene CD274 and neoplasm.